Sonablate
Device Facts
| Record ID | K160942 |
|---|---|
| Device Name | Sonablate |
| Applicant | Sonacare Medical, LLC |
| Product Code | PLP · Gastroenterology, Urology |
| Decision Date | Dec 21, 2016 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.4340 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Sonablate® is indicated for transrectal high intensity focused ultrasound (HIFU) ablation of prostatic tissue.
Device Story
Sonablate is a transrectal high intensity focused ultrasound (HIFU) system designed for prostate tissue ablation. The device utilizes ultrasound energy to thermally ablate targeted prostatic tissue. Operated by physicians in a clinical setting, the system provides real-time imaging for treatment planning and monitoring. The physician uses the device to deliver focused ultrasound waves to specific regions of the prostate, causing coagulative necrosis. This minimally invasive approach allows for localized treatment of prostatic tissue, potentially reducing morbidity compared to traditional surgical interventions. The system integrates imaging and therapeutic delivery to assist the clinician in achieving precise tissue destruction.
Clinical Evidence
No clinical data provided in the document; substantial equivalence is based on technological characteristics and performance comparisons to the predicate device.
Technological Characteristics
Transrectal high intensity focused ultrasound (HIFU) system. Utilizes ultrasound energy for thermal ablation. Includes integrated imaging for treatment planning and monitoring. Class II device under 21 CFR 876.4340 (Product Code: PLP).
Indications for Use
Indicated for transrectal high intensity focused ultrasound (HIFU) ablation of prostatic tissue in patients requiring such intervention. Prescription use only.
Regulatory Classification
Identification
A high intensity ultrasound system for prostate tissue ablation is a prescription device that transmits high intensity therapeutic ultrasound energy into the prostate to thermally ablate a defined, targeted volume of tissue, performed under imaging guidance. This classification does not include devices that are intended for the treatment of any specific prostate disease and does not include devices that are intended to ablate non-prostatic tissues/organs.
Special Controls
In combination with the general controls of the FD&C Act, the high intensity ultrasound system for prostate tissue ablation is subject to the following special controls:
*Classification.* Class II (special controls). The special controls for this device are:(1) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Characterization of acoustic pressure and power output at clinically relevant levels; (ii) Measurement of targeting accuracy and reproducibility of high intensity ultrasound output; (iii) Ultrasound-induced heating verification testing at target and non-target tissues; (iv) Electrical safety testing; and (v) Electromagnetic compatibility testing. (2) Software verification, validation, and hazard analysis must be performed. (3) The elements of the device that may contact the patient's mucosal tissue must be demonstrated to be biocompatible. (4) Performance data must demonstrate the sterility of the device components that contact the patient's mucosal tissue. (5) Performance data must support shelf life by demonstrating continued sterility of the device or the sterile components, package integrity, and device functionality over the identified shelf life. (6) Performance data must support the instructions for reprocessing all reusable components. (7) *In vivo* testing must demonstrate that the device thermally ablates targeted tissue in a controlled manner without thermal injury to adjacent, non-target tissues.(8) Clinical testing must document the adverse event profile, provide evidence of prostatic ablation, and demonstrate that the device performs as intended under anticipated conditions of use. (9) Training must be provided so that upon completion of the training program, the physician can: (i) Use all safety features of the device; (ii) Accurately target the high intensity ultrasound energy within the desired region of the prostate; and (iii) Perform the ablation procedure in a manner that minimizes damage to non-target tissues. (10) Labeling must include: (i) A section that summarizes the clinical testing results, including the adverse event profile and evidence of prostate ablation achieved; and (ii) An expiration date or shelf life for single use components.
Predicate Devices
- Sonablate 500 (K150203)